Literature DB >> 28424877

[Fuchs uveitis].

L Daas1, B Seitz2, U Pleyer3.   

Abstract

Fuchs uveitis (FU) is a frequent, chronic course of intraocular inflammation, which is associated with a gradual onset of decreased visual acuity. The clinical manifestation of the triad of heterochromia, cataract and glaucoma varies considerably. This explains the often delayed diagnosis. Although the aetiology and pathogenesis of the changes are still unclear, there is no doubt that infections play a significant role. Intraocular antibodies directed against rubella viruses show a high association with the disease pattern, and their detection can even be used to support the diagnosis. The treatment of FU is limited to symptomatic measures. Corticosteroids are usually only moderately effective and should be used with caution due to adverse effects, with progression of cataract and secondary glaucoma. The prognosis of the disease can be regarded as favourable and depends essentially on the secondary changes.

Entities:  

Keywords:  Anterior uveitis; Cytomegalovirus; Heterochromia; Inflammation; Rubella virus

Mesh:

Substances:

Year:  2017        PMID: 28424877     DOI: 10.1007/s00347-017-0494-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  53 in total

1.  Is there a genetic basis for Fuchs' heterochromic uveitis? Discordance in monozygotic twins.

Authors:  N P Jones; A P Read
Journal:  Br J Ophthalmol       Date:  1992-01       Impact factor: 4.638

2.  Heterochromia iridis and pertinent clinical findings in patients with glaucoma associated with Sturge-Weber syndrome.

Authors:  Nalini K Aggarwal; Sai B Gandham; Rebecca Weinstein; Robert Saltzmann; David S Walton
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2010-02-23       Impact factor: 1.402

3.  The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty.

Authors: 
Journal:  Am J Ophthalmol       Date:  2002-10       Impact factor: 5.258

4.  The causes of uveitis in a referral centre of Northern Italy.

Authors:  L Cimino; R Aldigeri; C Salvarani; C A Zotti; L Boiardi; M Parmeggiani; B Casali; L Cappuccini
Journal:  Int Ophthalmol       Date:  2010-03-14       Impact factor: 2.031

5.  Incidence and prevalence of different uveitis entities in Finland.

Authors:  T Päivönsalo-Hietanen; J Tuominen; H Vaahtoranta-Lehtonen; K M Saari
Journal:  Acta Ophthalmol Scand       Date:  1997-02

Review 6.  [Diagnostic and therapeutic aspects of herpes virus associated uveitis].

Authors:  U Pleyer; S Winterhalter
Journal:  Klin Monbl Augenheilkd       Date:  2010-05-20       Impact factor: 0.700

7.  Clinical analysis of Fuchs' heterochromic cyclitis.

Authors:  E La Hey; G S Baarsma; J De Vries; A Kijlstra
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

8.  Fuchs' heterochromic iridocyclitis revisited.

Authors:  I R Fearnley; A R Rosenthal
Journal:  Acta Ophthalmol Scand       Date:  1995-04

9.  Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients.

Authors:  Soon-Phaik Chee; Kristine Bacsal; Aliza Jap; Su-Yun Se-Thoe; Ching Li Cheng; Ban Hock Tan
Journal:  Am J Ophthalmol       Date:  2008-02-06       Impact factor: 5.258

10.  High concordance of intraocular antibody synthesis against the rubella virus and Fuchs heterochromic uveitis syndrome in Slovenia.

Authors:  Spela Stunf; Miroslav Petrovec; Nina Žigon; Marko Hawlina; Aleksandra Kraut; Jolanda D F de Groot-Mijnes; Nataša Vidovič Valentinčič
Journal:  Mol Vis       Date:  2012-12-01       Impact factor: 2.367

View more
  2 in total

1.  [Anterior viral uveitis : Clinical aspects, diagnostic procedure and treatment options].

Authors:  Matthias Lenglinger; Dominika Pohlmann; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

Review 2.  [Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Authors:  Roman Greslechner; Horst Helbig; Detlev Spiegel
Journal:  Ophthalmologe       Date:  2022-04-26       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.